Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Actinogen Medical (ACW)

Latest price

AUD0.03

— 0.00 (0.00)

As at 21/01/2025

Market capitalisation: AUD82m

View equity

Update

Healthcare

15.10.24

Actinogen Medical — A$11.1m capital raise completed

Update

Healthcare

07.10.24

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Flash note

Healthcare

27.08.24

NZD2.79

▾ −0.06 (−2.11)

As at 21/01/2025

Market capitalisation: NZD299m

View equity

Update

Healthcare

29.11.24

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

Flash note

Healthcare

04.11.24

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

Flash note

Healthcare

30.09.24

GBP0.06

— 0.00 (0.00)

As at 21/01/2025

Market capitalisation: GBP4m

View equity

Update

Healthcare

14.10.24

Argent Biopharma — Valuation report

QuickView

Healthcare

05.09.24

Argent Biopharma — An innovative approach to drug development

Update

Healthcare

04.11.19

CHF39.90

▾ −0.40 (−0.99)

As at 21/01/2025

Market capitalisation: CHF531m

View equity

Flash note

Healthcare

17.12.24

Basilea Pharmaceutica — Partner in place for US commercialisation of Zevtera

edison tv

Healthcare

10.12.24

Basilea Pharmaceutica – executive interview

Flash note

Healthcare

11.10.24

—

— 0.00 (0.00)

As at 21/01/2025

Market capitalisation: —

View equity

Cantargia (CANTA)

Latest price

SEK1.75

▾ −0.02 (−1.13)

As at 21/01/2025

Market capitalisation: SEK440m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

SEK5.10

▾ −0.10 (−1.92)

As at 21/01/2025

Market capitalisation: SEK1,462m

View equity

edison tv

Healthcare

28.11.24

Cereno Scientific – executive interview

Update

Healthcare

28.11.24

Cereno Scientific — A productive period with plenty more to come

Flash note

Healthcare

12.11.24

SEK0.78

▾ 0.11 (16.42)

As at 21/01/2025

Market capitalisation: SEK48m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

GBP0.19

— 0.00 (0.00)

As at 21/01/2025

Market capitalisation: GBP77m

View equity

Flash note

Healthcare

19.09.24

Creo Medical — Consumables business divested in strategic move

Flash note

Healthcare

05.07.24

Creo Medical — Intuitive deal expansion is a notable milestone

edison tv

Healthcare

04.06.24

—

— 0.00 (0.00)

As at 21/01/2025

Market capitalisation: —

View equity

Non client QV

Healthcare

20.01.25

USD2.04

— 0.00 (0.00)

As at 21/01/2025

Market capitalisation: USD57m

View equity

Outlook

Healthcare

15.01.25

Immix Biopharma — Shifting the ALA treatment paradigm with CAR-T

Flash note

Healthcare

04.10.24

Immix Biopharma — US CAR-T trial progresses to dose expansion

Update

Healthcare

14.08.24

SEK14.30

▾ −1.20 (−7.74)

As at 21/01/2025

Market capitalisation: SEK803m

View equity

Update

Healthcare

04.11.24

IRLAB Therapeutics — Progress across the pipeline in Q324

Flash note

Healthcare

08.10.24

IRLAB Therapeutics — IRL757 progress prompts $2.5m milestone payment

Flash note

Healthcare

03.10.24

EUR1.30

▾ 0.15 (13.22)

As at 21/01/2025

Market capitalisation: EUR17m

View equity

edison tv

Healthcare

29.10.24

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

edison tv

Healthcare

30.09.24

SEK7.97

▾ −0.53 (−6.24)

As at 21/01/2025

Market capitalisation: SEK414m

View equity

Update

Healthcare

03.01.25

Mendus — Regulatory endorsement supports vididencel focus

edison tv

Healthcare

19.12.24

Mendus – executive interview

Flash note

Healthcare

18.12.24

7.29

▾ 0.33 (4.64)

As at 21/01/2025

Market capitalisation: USD535m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

edison tv

Healthcare

20.04.23

MindMed update on major depressive disorder data: Rob Barrow, CEO

edison tv

Healthcare

29.03.23

CHF9.20

▾ 0.31 (3.49)

As at 21/01/2025

Market capitalisation: CHF178m

View equity

Update

Healthcare

17.01.25

Newron Pharmaceuticals — Spotlight on evenamide following licensing deals

Flash note

Healthcare

17.12.24

Newron Pharmaceuticals — Evenamide licence agreement in Japan

Update

Healthcare

23.09.24

Newron Pharmaceuticals — Moving full steam towards pivotal studies

See more
content on

Newron Pharmaceuticals

Equities

Equities by Sector

Sectors

Thematics

Latest

Why is gold hitting new highs?

Saba Capital campaign – Your vote matters

Market outlook: What lies ahead in 2025

Audiovisual

Latest

Uncovering Trusts – Saba Capital Campaign

Uncovering Trusts – Finsbury Growth & Income Trust (FGT)

Take on Trusts – December 2024

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.03

Actinogen Medical — A$11.1m capital raise completed

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Actinogen Medical — Further positive XanaCIDD results on depression

See morecontent on

AFT Pharmaceuticals (AFT)

NZD2.79

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

See morecontent on

Argent Biopharma (RGT)

GBP0.06

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF39.90

Basilea Pharmaceutica — Partner in place for US commercialisation of Zevtera

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Milestone march continues for Cresemba

See morecontent on

Biomea Fusion (BMEA)

—

Cantargia (CANTA)

SEK1.75

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK5.10

Cereno Scientific – executive interview

Cereno Scientific — A productive period with plenty more to come

Cereno Scientific — New SEK250m financing secures runway into 2026

See morecontent on

Chosa (CHOSA)

SEK0.78

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

See morecontent on

Creo Medical (CREO)

GBP0.19

Creo Medical — Consumables business divested in strategic move

Creo Medical — Intuitive deal expansion is a notable milestone

Creo Medical – executive interview with Craig Gulliford, CEO

See morecontent on

Herantis Pharma (HRTIS)

—

Herantis Pharma — Potential disease-modifier for PD

See morecontent on

Immix Biopharma (IMMX)

USD2.04

Immix Biopharma — Shifting the ALA treatment paradigm with CAR-T

Immix Biopharma — US CAR-T trial progresses to dose expansion

Immix Biopharma — Full steam ahead with US CAR-T trial

See morecontent on

IRLAB Therapeutics (IRLAB-A)

SEK14.30

IRLAB Therapeutics — Progress across the pipeline in Q324

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on